[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC: Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer; 2004 Jul 1;101(1):39-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric gastrointestinal stromal tumors and leiomyosarcoma.
  • BACKGROUND: With the introduction of molecularly targeted therapy for gastrointestinal stromal tumors (GISTs), it became important to distinguish GISTs from leiomyosarcomas (LMSs).
  • The authors sought to characterize the clinicopathologic features of these tumors in pediatric patients.
  • The authors also reviewed the literature pertaining to pediatric GISTs and LMSs.
  • Radiotherapy or chemotherapy was used to treat one patient with GISTs and three patients with LMS.
  • Surgery was the treatment of choice for both entities, and tumor resectability was a key prognostic factor.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Leiomyosarcoma / pathology. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15221987.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 23099
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


2. Kato K, Arai K, Tanaka Y, Ijiri R, Kato Y, Kigasawa H, Toyoda Y, Aida N, Ohama Y: Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors". Mod Pathol; 2000 Oct;13(10):1156-60
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors".
  • We report an 18-month-old Japanese girl with purely epithelioid leiomyosarcoma presenting as a huge intraabdominal mass.
  • The age, clinical presentation, and histologic findings mostly favored Ewing's sarcoma/primitive neuroectodermal tumor.
  • Silver stain, however, demonstrated well-developed reticulin fibers often outlining individual tumor cells.
  • The diagnosis of epithelioid leiomyosarcoma was made.
  • Following reduction in tumor size by chemotherapy, the serum NSE level was normalized.
  • Although extremely rare, epithelioid leiomyosarcoma should be added in the list of differential diagnoses of pediatric "round cell tumors. "
  • [MeSH-major] Abdominal Neoplasms / pathology. Immunocompromised Host. Leiomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048812.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


3. Cecchetto G, Alaggio R, Dall'Igna P, Bisogno G, Ferrari A, Gigante C, Casanova M, Sotti G, Zanetti I, Carli M: Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer; 2005 Nov 1;104(9):2006-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies.
  • BACKGROUND: Treatment of initially unresectable nonrhabdo soft tissue sarcomas (NRSTS) in pediatric age is debated, due to their different chemosensitivity.
  • The authors objective was to evaluate clinical features and treatment results observed in a series of Italian patients over a 24-year period.
  • Therapeutic guidelines recommended an initial biopsy plus neoadjuvant chemotherapy.
  • Chemosensitive (CTs) sarcomas, 21: synovial sarcoma, 11; extraosseous Ewing sarcomas, 5; primitive peripheral neuroectodermic tumors, 5.
  • Nonchemosensitive (CTns) sarcomas, 31: fibrosarcoma, 11; malignant peripheral nerve sheet tumors, 10; liposarcoma, 2; hemangiopericitoma adult type, 2; epithelioid sarcoma, 2; and alveolar soft part sarcoma, leiomyosarcoma, clear cell sarcoma, and sarcoma NOS, each 1.
  • Response to neoadjuvant chemotherapy was complete or partial in 10 of 20 evaluable CTs and in 8 of 26 evaluable CTns tumors.
  • Tumor size < 5 cm, distal site, and tumor grading for CTns sarcomas were often linked to a favorable outcome; no conclusive results were detected concerning age of the patients or T status of the tumor.
  • CONCLUSIONS: Multidisciplinary treatment without mutilating procedures allowed the cure of most patients with CTs and CTns-NRSTS.
  • [MeSH-major] Extremities. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Age Factors. Chemotherapy, Adjuvant. Child. Female. Humans. Italy. Male. Neoadjuvant Therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16161038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Blaise G, Nikkels AF, Quatresooz P, Hermanns-Lê T, Piérard GE: Childhood cutaneous leiomyosarcoma. Pediatr Dermatol; 2009 Jul-Aug;26(4):477-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood cutaneous leiomyosarcoma.
  • Cutaneous leiomyosarcoma is a soft tissue neoplasm exhibiting an aggressive local behavior and a potential for distant metastases.
  • It is rare during childhood and diagnosis can be challenging both clinically and histologically.
  • Surgical excision with wide lateral and deep margins is the treatment of choice, whereas radiotherapy and chemotherapy are contraindicated.
  • [MeSH-major] Leiomyosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child. Dermatofibrosarcoma / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Microscopy, Electron. Skin Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689533.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Dhall D, Al-Ahmadie HA, Dhall G, Shen-Schwarz S, Tickoo SK: Pediatric renal cell carcinoma with oncocytoid features occurring in a child after chemotherapy for cardiac leiomyosarcoma. Urology; 2007 Jul;70(1):178.e13-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric renal cell carcinoma with oncocytoid features occurring in a child after chemotherapy for cardiac leiomyosarcoma.
  • We report a case of renal cell carcinoma (RCC) with extensive oncocytoid features developing in a 12-year-old African-American boy after chemotherapy for cardiac leiomyosarcoma at 3 months of age.
  • The tumor showed histopathologic features similar to those previously reported in RCC after chemotherapy for neuroblastoma and now considered a specific entity in the World Health Organization classification of renal tumors as "RCC associated with neuroblastoma."
  • Our report expands the spectrum of tumors (beyond neuroblastoma) in which RCCs with such an appearance can arise in the pediatric age group after chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Heart Neoplasms / drug therapy. Kidney Neoplasms / pathology. Leiomyosarcoma / drug therapy. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656235.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Ferrari A, Bisogno G, Casanova M, Meazza C, Cecchetto G, Mancini MA, Zanetti I, Alaggio R, Ninfo V, Carli M: Childhood leiomyosarcoma: a report from the soft tissue sarcoma Italian Cooperative Group. Ann Oncol; 2001 Aug;12(8):1163-8
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leiomyosarcoma: a report from the soft tissue sarcoma Italian Cooperative Group.
  • BACKGROUND: Only a few reports on the clinical features and management of childhood leiomyosarcoma are available.
  • To contribute additional information on the management of this rare tumor, we report on a series of 16 pediatric patients treated from 1982 to 1998 by the Soft Tissue Sarcoma Italian Cooperative Group.
  • In two cases secondary radical surgery was performed after primary chemotherapy.
  • Chemotherapy was administered to 9 of 16 patients, radiotherapy to three.
  • CONCLUSIONS: Complete surgical resection is the mainstay of treatment for leiomyosarcoma.
  • The role of both adjuvant chemotherapy and radiotherapy has yet to be established, and awaits cooperative multicentric studies.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11583201.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Bisogno G, Sotti G, Nowicki Y, Ferrari A, Garaventa A, Zanetti I, Favre C, Schiavetti A, Tamaro P, Carli M: Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer; 2004 Apr 15;100(8):1758-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group.
  • BACKGROUND: Survivors of childhood malignancies have an increased risk of developing second malignant neoplasms (SMN) due to their prior treatment and/or genetic susceptibility.
  • A small proportion of SMNs are soft tissue sarcomas (STS), whose prognosis is generally thought to be poor, though publications on such patients' treatment and outcome is limited.
  • METHODS: The authors analyzed 25 patients who were registered for the Italian Cooperative Group protocols for pediatric STS from 1979 to 2000.
  • The primary tumor was STS in five patients; Hodgkin disease in five patients; leukemia in four patients; retinoblastoma, neuroblastoma, and Wilms tumor in two patients each; and other tumor types in five patients.
  • SMNs occurred after a median of 8 years (range, 1.9-15.0 years) and included rhabdomyosarcoma (RMS) in 4 patients, malignant peripheral nerve sheath tumor in 4 patients, extraosseous Ewing family tumor (EFT) in 4 patients, leiomyosarcoma in 3 patients, fibrosarcoma in 2 patients, synovial sarcoma in 2 patients, and other tumor types in 6 patients.
  • Treatment generally was administered according to the guidelines for primary STS.
  • RESULTS: Seven non-RMS patients with STS underwent surgery alone, whereas 18 patients received chemotherapy and 8 patients received radiotherapy.
  • Fifteen patients were alive in complete remission of their SMN at the time of last follow-up.
  • Responses to chemotherapy and survival were satisfactory for patients with tumors such as RMS and EFT.
  • Complete tumor resection was correlated with a favorable prognosis in patients with other types of STS and in patients with postirradiation sarcoma.
  • Two patients developed a third malignancy.
  • CONCLUSIONS: Although prior treatment may hinder the management of these patients, pediatric STS second malignancies can be cured using the same strategies used for de novo pediatric sarcomas.
  • Long-term follow-up is mandatory given the risks of further malignancies and more severe, treatment-related side effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15073867.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Wakhlu A, Chaudhary A: Massive leiomyosarcoma of the testis in an infant. J Pediatr Surg; 2004 Jul;39(7):e16-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive leiomyosarcoma of the testis in an infant.
  • Leiomyosarcoma of the testis is a very rare tumor in children.
  • This report describes a massive leiomyosarcoma of the left testis in an infant that was treated successfully by excision and chemotherapy.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Leiomyosarcoma / surgery. Testicular Neoplasms / diagnosis. Testicular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Humans. Infant. Male. Testis / pathology. Testis / surgery. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15213939.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Parekh DJ, Jung C, O'Conner J, Dutta S, Smith ER Jr: Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology; 2002 Jul;60(1):164
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas.
  • We report an unusual case of a leiomyosarcoma of the urinary bladder after chemotherapy for retinoblastoma and the results of a review of the published reports of bladder sarcomas.
  • A 22-year-old man presented with hematuria and was found to have a mass in his urinary bladder on computed tomography.
  • Transurethral resection of the mass revealed a leiomyosarcoma.
  • The final pathologic examination confirmed high-grade leiomyosarcoma.
  • Prospective randomized combination trials similar to the Intergroup Rhabdomyosarcoma Study in the pediatric population are necessary to better understand and manage these potentially curable sarcomas.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Leiomyosarcoma / diagnosis. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100953.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 13
  •  go-up   go-down


10. Sethi A, Mrig S, Sethi D, Mandal AK, Agarwal AK: Parotid gland leiomyosarcoma in a child: an extremely unusual neoplasm. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul;102(1):82-4
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland leiomyosarcoma in a child: an extremely unusual neoplasm.
  • We report the case of an 8-year-old boy with a parotid mass diagnosed to be a leiomyosarcoma.
  • The patient developed distant metastasis following the course of radiotherapy and was put on chemotherapy.
  • To our knowledge, this is the first reported case in the English-language literature of such an entity in the pediatric age group.
  • [MeSH-major] Leiomyosarcoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831677.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


11. Brichard B, Smets F, Sokal E, Clapuyt P, Vermylen C, Cornu G, Rahier J, Otte JB: Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation. Pediatr Transplant; 2001 Oct;5(5):365-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
  • We report the case of a child who developed, 2 yr after orthotopic liver transplantation (OLTx) for biliary atresia, a multi-focal hepatic tumor with lymphonodular metastases, identified as an Epstein-Barr virus (EBV)-associated leiomyosarcoma.
  • Chemotherapy was given without tumor response.
  • At the present time, 12 yr after the discovery of the first hepatic lesions, the patient is alive and completely symptom-free, the abdominal masses are stable, and liver function tests are completely normal.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Leiomyosarcoma / virology. Liver Neoplasms / virology. Liver Transplantation / immunology. Postoperative Complications / immunology


12. Gehrmann J, Kehl HG, Diallo R, Debus V, Vogt J: Cardiac leiomyosarcoma of the right atrium in a teenager: unusual manifestation with a lifetime history of atrial ectopic tachycardia. Pacing Clin Electrophysiol; 2001 Jul;24(7):1161-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac leiomyosarcoma of the right atrium in a teenager: unusual manifestation with a lifetime history of atrial ectopic tachycardia.
  • Transesophageal echocardiography revealed a right atrial leiomyosarcoma.
  • Her past medical history was remarkable for incessant atrial ectopic tachycardia (AET) beginning in early infancy and continuing throughout childhood and adolescence that was refractive to medical and nonpharmacological treatment.
  • After combined surgical and medical therapy, normal sinus rhythm was restored and the patient is currently in complete remission with no recurrent symptoms or atrial arrhythmias at 31 months after surgery and 23 months after the discontinuation of chemotherapy.
  • [MeSH-major] Heart Atria. Heart Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Tachycardia, Ectopic Atrial / complications

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11475835.001).
  • [ISSN] 0147-8389
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Mathieson CS, St George EJ, Stewart W, Sastry J, Jamal S: Primary intracranial leiomyosarcoma: a case report and review of the literature. Childs Nerv Syst; 2009 Aug;25(8):1013-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracranial leiomyosarcoma: a case report and review of the literature.
  • INTRODUCTION: Malignant tumours of the central nervous system (CNS) represent the second most common cancer type in the paediatric population of developed countries, and mortality caused by CNS tumours is the highest among paediatric cancers.
  • This paper describes the case of a 5-year-old non-immunocompromised male who presented with a right frontal primary intracranial leiomyosarcoma associated with large subdural collections.
  • The literature is reviewed and the possible association of the chronic subdurals to the later development of the leiomyosarcoma explored.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Leiomyosarcoma / drug therapy. Leiomyosarcoma / radiotherapy
  • [MeSH-minor] Brain / diagnostic imaging. Brain / pathology. Child, Preschool. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1999 Jan;41(1):35-9 [9987766.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jan-Feb;15(1):166-7 [1987192.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Aug;99(3):210-2 [9350403.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1550-4 [1893356.001]
  • [Cites] J Neurosurg. 1989 Aug;71(2):279-82 [2746352.001]
  • [Cites] Neurology. 1999 May 12;52(8):1648-51 [10331693.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(12):1470-1 [9030357.001]
  • [Cites] Med Princ Pract. 2002 Jul-Sep;11(3):157-60 [12138299.001]
  • [Cites] J Neurosurg. 1980 Sep;53(3):401-5 [7420156.001]
  • [Cites] Acta Neurol (Napoli). 1971 May-Jun;26(3):297-302 [5094470.001]
  • [Cites] No Shinkei Geka. 1988 May;16(6):747-52 [3412561.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Sep-Oct;8(5):911-2 [3118683.001]
  • [Cites] Clin Infect Dis. 2005 May 15;40(10):1521-8 [15844077.001]
  • [Cites] Clin Neuropathol. 1995 Jul-Aug;14 (4):245-8 [8521631.001]
  • [Cites] J Neurosurg. 1968 Aug;29(2):189-91 [5673316.001]
  • [Cites] Neurosurgery. 1999 Jan;44(1):199-202 [9894982.001]
  • [Cites] J Neurosurg. 1988 Feb;68(2):308-11 [3339450.001]
  • [Cites] Histopathology. 1991 May;18(5):395-402 [1715839.001]
  • [Cites] J Med Assoc Thai. 2004 Sep;87 Suppl 2:S152-60 [16083180.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):179-83 [9892100.001]
  • (PMID = 19308428.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 22
  •  go-up   go-down


14. Lai DS, Lue KH, Su JM, Chang H: Primary bronchopulmonary leiomyosarcoma of the left main bronchus in a child presenting with wheezing and atelectasis of the left lung. Pediatr Pulmonol; 2002 Apr;33(4):318-21
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bronchopulmonary leiomyosarcoma of the left main bronchus in a child presenting with wheezing and atelectasis of the left lung.
  • We report on the eleventh case of primary bronchopulmonary leiomyosarcoma in a child, and it is the first case in Taiwan, and also in Asia.
  • Chest roentgenogram and bronchoscopy are helpful in the diagnosis of primary bronchopulmonary tumors, but a definitive diagnosis can only be made by biopsy.
  • The tumor is potentially curable if total excision is possible; irradiation has little therapeutic value, and early excision offers the only hope of cure.
  • The child is alive and well 19 months after pneumonectomy, without having received radiotherapy or chemotherapy.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Lung Neoplasms / diagnosis. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11921463.001).
  • [ISSN] 8755-6863
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


15. Mugishima H, Matsunaga T, Yagi K, Asami K, Mimaya J, Suita S, Kishimoto T, Sawada T, Tsuchida Y, Kaneko M: Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol; 2002 Feb;24(2):94-100
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of irinotecan in pediatric patients with malignant solid tumors.
  • Fifty-one treatment courses were administered to these patients.
  • CONCLUSION: The maximum tolerated dose was determined to be a dose of irinotecan between 160 mg/m2 per day and 180 mg/m2 per day administered over the course of 3 consecutive days on an inpatient basis, repeated once after 25 days off, and our results indicate that irinotecan is a promising anticancer agent that is worthy of phase II trials in pediatric solid tumors.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Bone Marrow Diseases / chemically induced. Camptothecin / therapeutic use. Diarrhea / chemically induced. Enzyme Inhibitors / therapeutic use. Neuroblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug-Induced Liver Injury / etiology. Female. Humans. Infusions, Intravenous. Japan. Leiomyosarcoma / drug therapy. Male. Maximum Tolerated Dose. Metabolic Clearance Rate. Neoplasm Proteins / antagonists & inhibitors. Neuroectodermal Tumors, Primitive / blood. Neuroectodermal Tumors, Primitive / drug therapy. Topoisomerase I Inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2002 Feb;24(2):84-5 [11990709.001]
  • (PMID = 11990713.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


16. Antoniello L, Cecchetto G, Carli M, Dall'Igna P, Bisogno G, Lo Piccolo R, Gigante C, Zanetti I, Guglielmi M: [Role of mutilating surgery in the treatment of non-chemosensitive pediatric soft tissue sarcomas. Experience of the Italian Cooperative Group Studies RMS-79 and RMS-88]. Pediatr Med Chir; 2003 Jul-Aug;25(4):255-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of mutilating surgery in the treatment of non-chemosensitive pediatric soft tissue sarcomas. Experience of the Italian Cooperative Group Studies RMS-79 and RMS-88].
  • Aim of the study was to evaluate the role of mutilating surgery in the patients with non chemosensitive soft tissue sarcomas (STS) registered in the Italian Studies.
  • HISTOLOGY: fibrosarcoma 29, Malignant Perpheral Nerve Sheath Tumors (MPNST) 40, malignant fibrous histiocytoma 5, hemangiopericytoma 6, leiomyosarcoma 4, others 20, STS nos 10.
  • The mutilating procedure was carried out at diagnosis in 6 cases (4 in RMS-79 and 2 in RMS-and 88) and achieved radicality in 5/6 cases.
  • It was performed after ineffective chemotherapy (CT) in 5 pts (1 in RMS-79 and 4 in RMS-88).
  • CONCLUSIONS: In the RMS-79 study the mutilations were frequent and were performed at diagnosis in several cases; this trend decreased in the 2nd study in which chemotherapy was attempted in most of the patients.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15070267.001).
  • [ISSN] 0391-5387
  • [Journal-full-title] La Pediatria medica e chirurgica : Medical and surgical pediatrics
  • [ISO-abbreviation] Pediatr Med Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


17. Brichard B, Vermylen C, Gosseye S, Otte JB, Cornu G: Smooth muscle tumor developing in an immunocompromised child after therapy for leukemia. J Pediatr Hematol Oncol; 2001 Feb;23(2):139-41
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle tumor developing in an immunocompromised child after therapy for leukemia.
  • Macroscopically complete resection of the abdominal tumors was performed and revealed a well-differentiated leiomyosarcoma.
  • [MeSH-major] Abdominal Neoplasms / etiology. Anthracyclines / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / adverse effects. Cortisone / adverse effects. Hematopoietic Stem Cell Transplantation. Immunologic Deficiency Syndromes / complications. Leiomyosarcoma / etiology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Neoplasms, Second Primary / etiology. Transplantation Conditioning / adverse effects. Vincristine / adverse effects. Whole-Body Irradiation / adverse effects

  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11216708.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 5J49Q6B70F / Vincristine; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; V27W9254FZ / Cortisone; FRALLE 93 protocol
  •  go-up   go-down


18. Méndez R, Arnáiz S, Montero M, Tellado M, País E, Ríos J, Vela D: [Clinical patterns of soft-tissue sarcoma in children]. Cir Pediatr; 2001 Jan;14(1):14-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical patterns of soft-tissue sarcoma in children].
  • INTRODUCTION AND OBJECTIVES: Soft tissue sarcomas are rare mesenchymal neoplasms that constitute less than 10% of all pediatric malignancies.
  • Half of these are rhabdomyosarcomas, the remaining 50% have a varied and heterogenous histologic and clinical patterns (fibrosarcoma, synovial cell sarcoma, extraskeletal Ewing's sarcoma, angiosarcoma, liposarcoma, leiomyosarcoma, ...).
  • The purpose of this work is to evaluate our clinical experience with soft tissue sarcomas in uncommon sites over the past 10 years in order to delimitate the prognostic factors in survival and modalities of treatment.
  • MATERIAL AND METHODS: Between 1989 and 1998, 10 patients were diagnosed with soft tissue sarcomas in uncommon sites and treated by us over a total number of 139 pediatric neoplasms (7.19%).
  • Variables investigated included histologic findings, tumor size, age at presentation, primary site, clinical group, radiologic test performed, surgical treatment, radiotherapy and adjuvant chemotherapy, complications and survival rates.
  • RESULTS: The following histologic types of these 10 tumors were identified: 1 hemangiopericytoma in oral cavity, 2 extraosseous Ewing's sarcoma, 1 botryoid rhabdomyosarcoma of the bladder, 1 mediastinal fibrosarcoma, 1 retroperitoneal rhabdomyosarcoma, 1 paratesticular rhabdomyosarcoma, 1 cervical condrosarcoma, 1 alveolar rhabdomyosarcoma and 1 deltoid rhabdomyosarcoma.
  • Adjuvant chemotherapy with IVA was followed by radiotherapy only in four patients.
  • All the children classified in clinical groups II, III or IV needed 2nd. line regimens of chemotherapy.
  • Three patients died in the follow-up instead of the multimodal treatment.
  • 2) radiotherapy will only be necessary if margins of resection cannot control the local disease, and 3) chemotherapy have not clearly demonstrated his benefits as adjuvant therapy in clinical group I lesions but his employ is recommended in all cases because of the poor prognosis due to local recurrence.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


19. Hensley ML: Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol; 2010 Jul;22(4):356-61
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
  • PURPOSE OF REVIEW: The combination of fixed-dose-rate gemcitabine and docetaxel has become an established treatment option for advanced uterine leiomyosarcoma and has demonstrated efficacy in nonleiomyosarcoma histology soft-tissue sarcomas.
  • The activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discussed.
  • RECENT FINDINGS: Fixed-dose-rate gemcitabine and docetaxel achieved high objective response rates in three prospective phase II studies as first-line or second-line therapy for advanced uterine leiomyosarcoma.
  • In a randomized trial, the combination of gemcitabine and docetaxel was superior to gemcitabine alone in terms of objective response, progression-free, and overall survival among patients with soft-tissue sarcoma, most of whom had received at least one prior cytotoxic regimen.
  • In a prospective phase II trial, four of 10 pediatric patients with sarcomas achieved complete responses with this regimen.
  • In a small, prospective phase II trial for women with completely resected stage I, II, III, or IV high-grade uterine leiomyosarcoma, adjuvant treatment with gemcitabine-docetaxel was associated with a 2-year progression-free survival rate that appears superior to that of historical controls.
  • SUMMARY: Fixed-dose-rate gemcitabine and docetaxel is a reasonable treatment option for patients with advanced soft-tissue sarcoma.
  • The regimen is a good choice as first-line or second-line therapy for advanced uterine leiomyosarcoma.
  • The role of adjuvant gemcitabine-docetaxel in completely resected, uterine-limited, high-grade leiomyosarcoma is under investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Humans. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20520541.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 34
  •  go-up   go-down


20. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a marked female preponderance and approximately one-third of the cases occur in the pediatric age group.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Janet NL, May AW, Akins RS: Sarcoma of the prostate: a single institutional review. Am J Clin Oncol; 2009 Feb;32(1):27-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma of the prostate: a single institutional review.
  • OBJECTIVE: We report the management and outcome of prostate sarcoma at 1 institution and analyze factors that may determine prognosis.
  • MATERIALS AND METHODS: The medical records of 10 patients with prostate sarcoma were reviewed to identify symptoms at presentation, diagnostic procedures, and staging methods.
  • Histology, grade, tumor size, stage, and treatment modality were analyzed.
  • RESULTS: Five patients had rhabdomyosarcoma (RMS) and five had other subtypes, including two with carcinosarcoma, two with high-grade sarcoma not-otherwise-specified, and one with leiyomyosarcoma.
  • Eight patients presented with locally advanced disease and two with metastatic disease.The two metastatic patients received chemotherapy, and one also had hormonal ablation therapy.
  • Of the eight with local disease, two had neoadjuvant chemotherapy and surgery, one had surgery alone, one had surgery and postoperative radiation, one had radiation alone, and three had chemoradiation.Chemotherapy consisted of vincristine, adriamycin, and cyclophosphomide for rhabdomyosarcoma and of cisplatin, adriamycin, and ifosphamide for the other subtypes.
  • Radiation dose ranged from 40 Gy to 55.8 Gy.The median survival follow-up of the study is 46.5 months.
  • There were three deaths, of which two had metastatic disease at presentation and one later developed distant metastases after having surgery alone.
  • One patient developed a local recurrence 47 months after chemoradiation and was successfully salvaged with surgery.
  • CONCLUSIONS: In terms of tumor-related factors, the histologic subtype of prostate sarcoma appears to have prognostic significance.
  • Pediatric patients with RMS faired much better with a median survival of over 10 years.
  • The presence of metastatic disease at diagnosis, however, is a poor predictor of outcome.In terms of treatment-related factors, surgery alone is inadequate treatment.
  • One patient treated with surgery alone developed distant metastases 38 months later, then received chemotherapy and hormonal therapy, and died at 58 months.
  • Patients who received combined modality treatment appear to fare better.Finally, these patients need long term follow-up.
  • One patient developed a local recurrence 47 months after chemoradiation.
  • [MeSH-major] Carcinosarcoma / therapy. Leiomyosarcoma / therapy. Prostatic Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Medical Records. Middle Aged. Prognosis. Prostatectomy. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194120.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Raffensperger J, Krueger R: Carney's triad: a 16-year follow-up. J Pediatr Surg; 2007 Aug;42(8):1452-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She later developed a pulmonary chondroma, fulfilling the requirements of Carney's triad.
  • [MeSH-major] Chondroma / pathology. Ganglioneuroma / pathology. Leiomyosarcoma / pathology. Lung Neoplasms / pathology. Mediastinal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antidepressive Agents / therapeutic use. Combined Modality Therapy. Depressive Disorder / complications. Depressive Disorder / drug therapy. Fatal Outcome. Female. Follow-Up Studies. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Syndrome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706515.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


23. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Shitara T, Shimada A, Hanada R, Matsunaga T, Kawa K, Mugishima H, Sugimoto T, Mimaya J, Manabe A, Tsurusawa M, Tsuchida Y: Irinotecan for children with relapsed solid tumors. Pediatr Hematol Oncol; 2006 Mar;23(2):103-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Irinotecan is expected to become a new drug for childhood solid tumors.
  • Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each.
  • Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2.
  • Irinotecan appears promising, and could become included in the first-line treatment.
  • [MeSH-major] Camptothecin / analogs & derivatives. Neoplasms / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Infant. Male. Neuroblastoma / drug therapy. Recurrence. Remission Induction. Rhabdomyosarcoma / drug therapy. Tumor Burden / drug effects. Wilms Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2009 Jan;52(1):145 [18798559.001]
  • (PMID = 16651238.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Ferrari A, Collini P, Casanova M, Meazza C, Podda M, Mazza EA: Response to chemotherapy in a child with primary bronchopulmonary leiomyosarcoma. Med Pediatr Oncol; 2002 Jul;39(1):55-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to chemotherapy in a child with primary bronchopulmonary leiomyosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / drug therapy. Leiomyosarcoma / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Child, Preschool. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12116083.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement